This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Europe's premier partnering event
November 4–6, 2024 | Stockholm, SwedenNovember 12–13, 2024 | Digital Partnering

Peter Nell
Co-founder and CEO at Stealthmode Company


Peter Nell is currently building a new stealth mode gene editing company as a spin-out out of a private life science company. Through the end of April 2022, he was Chief Business Officer and Head of Therapeutics Strategy at Mammoth Biosciences, a CRISPR-focused company co-founded by Nobel Laureate Jennifer Doudna. Peter established Mammoth’s entry into therapeutics research and was responsible for two partnerships with Bayer and Vertex Pharmaceuticals. 2015/16, Peter co-founded Casebia Tx as a Joint Venture between Bayer and CRISPR Tx where he was responsible for corporate strategy and business development. Casebia Tx was fully acquired by CRISPR Tx in 2019.
Peter entered the world of entrepreneurship after sixteen years at Bayer where he worked in various positions both in Germany and the US, including Medicinal Chemistry Research, a Chief of Staff position, Operations, BD&L, Alliance Management and Strategic Marketing. During his time at Bayer, Peter was involved in establishing the incubator model of Bayer with the CoLaborator in San Francisco and was responsible for several in-licensing deals covering the whole spectrum of modalities from small molecules to gene therapy with global coverage. He was in the lucky position to be co-inventor of a product that made it to the commercial stage fulfilling his ambition to help patients with novel treatments.
Peter received his education from the Universities of Freiburg, Heidelberg, Bristol, and Marburg, graduating with a PhD in Organic Chemistry followed by postdoctoral studies at Stanford.

Agenda Sessions

  • Choose the right ingredients for successful collaborations between biotech startups and big pharma